The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers

This publication has 48 references indexed in Scilit:

• Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling
  European Journal Of Cancer, 2005
• Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers
  European Journal Of Cancer, 2004
• LuCaP 35: A new model of prostate cancer progression to androgen independence
  The Prostate, 2003
• GH–RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells
  Life Sciences, 2003
• Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor
  The Prostate, 2002
• Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
  The Prostate, 1997
• Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
  European Journal Of Cancer, 1997
• Vascular endothelial growth factor
  European Journal Of Cancer, 1996
• New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analogues
  International Journal of Peptide and Protein Research, 1988
• Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding.
  The Journal of cell biology, 1986